XML 52 R6.htm IDEA: XBRL DOCUMENT v2.4.0.8
CONSOLIDATED STATEMENT OF STOCKHOLDERS' DEFICIT (USD $)
In Thousands, unless otherwise specified
Total
4.75% Convertible Senior Notes due 2015
0.375% convertible senior notes due 2018 and 1.25% convertible senior notes due 2020
Common Stock
Additional Paid-in Capital
Additional Paid-in Capital
4.75% Convertible Senior Notes due 2015
Additional Paid-in Capital
0.375% convertible senior notes due 2018 and 1.25% convertible senior notes due 2020
Accumulated Other Comprehensive Income (Loss)
Accumulated Deficit
Balances at Dec. 31, 2010 $ (88,644)     $ 123 $ 1,332,277     $ 1,986 $ (1,423,030)
Increase (Decrease) in Stockholders' Equity                  
Issuance of 6,898,551, 5,150,649 and 2,294,586 shares of Common Stock upon exercise of stock options and restricted stock units and 390,000, 378,041 and 896,939 shares of Common Stock under the ESPP for the years ended 2013, 2012 and 2011, respectively 19,468     3 19,465        
Stock compensation expense 28,983       28,983        
Other comprehensive (loss) income (344)             (344)  
Net loss (186,540)               (186,540)
Balances at Dec. 31, 2011 (227,077)     126 1,380,725     1,642 (1,609,570)
Increase (Decrease) in Stockholders' Equity                  
Issuance of 6,898,551, 5,150,649 and 2,294,586 shares of Common Stock upon exercise of stock options and restricted stock units and 390,000, 378,041 and 896,939 shares of Common Stock under the ESPP for the years ended 2013, 2012 and 2011, respectively 47,711     5 47,706        
Issuance of 1,025,641 and 1,461,496 shares of Common Stock upon conversion of Pfizer Note for the years ended 2013 and 2012, respectively and 21,208,303 shares of Common Stock upon conversion of Convertible Senior Notes due 2015 for the years ended 2013 10,000     2 9,998        
Stock compensation expense 38,493       38,493        
Other comprehensive (loss) income 236             236  
Net loss (44,320)               (44,320)
Balances at Dec. 31, 2012 (174,957)     133 1,476,922     1,878 (1,653,890)
Increase (Decrease) in Stockholders' Equity                  
Issuance of 6,898,551, 5,150,649 and 2,294,586 shares of Common Stock upon exercise of stock options and restricted stock units and 390,000, 378,041 and 896,939 shares of Common Stock under the ESPP for the years ended 2013, 2012 and 2011, respectively 73,157     7 73,150        
Issuance of 1,025,641 and 1,461,496 shares of Common Stock upon conversion of Pfizer Note for the years ended 2013 and 2012, respectively and 21,208,303 shares of Common Stock upon conversion of Convertible Senior Notes due 2015 for the years ended 2013 9,373     1 9,372        
Issuance of 21,208,303 shares of Common Stock for 2013 154,338     22 154,316        
Reclassification to additional paid in capital in connection with repurchase of convertible senior notes   (381,405)       (381,405)      
Equity component in convertible notes     170,806       170,806    
Excess tax benefit from stock based compensation 214       214        
Stock compensation expense 38,398       38,398        
Other comprehensive (loss) income 115             115  
Net loss (83,147)               83,147
Balances at Dec. 31, 2013 $ (193,108)     $ 163 $ 1,541,773     $ 1,993 $ (1,737,037)